/SANA
SANA Stock - Sana Biotechnology, Inc.
Healthcare|BiotechnologyNASDAQ
$4.36-3.11%
$0.14 (-3.11%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.72
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.42
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+83.5%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SANA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.32 – $4.40
TARGET (TP)$8.00
STOP LOSS$4.01
RISK/REWARD1:10.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.96
52W High$7.30
52W Low$1.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-10,171,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-272,723,000 | $-293,141,000 | $-272,564,000 | $-356,909,000 | $-161,123,000 |
| Net Income | $-266,759,000 | $-283,255,000 | $-269,476,000 | $-355,928,000 | $-285,305,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.16 | $-1.46 | $-1.43 | $-2.14 | $-1.63 |
Company Overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
89%
Hold / Neutral
1
11%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish1 Neutral/Bearish
Price Targets
$9
Average Target
↑ 112.2% Upside
Now
$5
Low
$9
Average
$16
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 24th 2025 | Wedbush | Initiation | Outperform | $5 |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $12 |
| March 18th 2025 | Citizens JMP | Upgrade | Mkt Outperform | $5 |
| March 14th 2025 | Jefferies | Initiation | Buy | $7 |
| January 8th 2025 | TD Cowen | Upgrade | Buy | - |
| November 5th 2024 | JMP Securities | Downgrade | Market Perform | - |
| June 26th 2024 | Rodman & Renshaw | Initiation | Buy | $16 |
| January 16th 2024 | H.C. Wainwright | Upgrade | Buy | $12 |
| September 25th 2023 | JMP Securities | Initiation | Mkt Outperform | $9 |
| September 5th 2023 | Citigroup | Initiation | Buy | $8 |
| August 14th 2023 | TD Cowen | Initiation | Market Perform | - |
| May 2nd 2023 | H.C. Wainwright | Initiation | Neutral | - |
Earnings History & Surprises
SANABeat Rate
50%
Last 18 quarters
Avg Surprise
-17.8%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
+5.4%
$-0.35vs$-0.37
Q2 24
-6.7%
$-0.32vs$-0.30
Q3 24
-18.5%
$-0.32vs$-0.27
Q4 24
+3.8%
$-0.25vs$-0.26
Q1 25
+8.0%
$-0.23vs$-0.25
Q2 25
+9.1%
$-0.20vs$-0.22
Q3 25
+20.0%
$-0.16vs$-0.20
Q4 25
+16.7%
$-0.15vs$-0.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.27 | $-0.32 | -18.5% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.37 | $-0.35 | +5.4% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.42 | $-0.41 | +2.4% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.39 | $-0.48 | -23.1% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.46 | $-0.47 | -2.2% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.38 | $-0.47 | -23.7% | ✗ MISS |
Q1 2022 | Mar 16, 2022 | $0.36 | $-0.65 | -280.6% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.29 | $-0.37 | -27.6% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.37 | $-0.32 | +13.5% | ✓ BEAT |
Latest News
Sana Biotechnology Says Nature Biotechnology Publishes Journal Article Titled "In Vivo Gene Editing Of Human Hematopoietic Stem And Progenitor Cells Using Envelope-Engineered Virus-Like Particles"
📈 PositiveBenzinga•Dec 8, 2025, 02:05 PM
Watching Shares Of Sana Biotech; Investor Eric Jackson On Fox Business Mentions The Stock
➖ NeutralBenzinga•Nov 26, 2025, 07:37 PM•Also: ,
Wedbush Maintains Outperform on Sana Biotechnology, Raises Price Target to $6
📈 PositiveBenzinga•Nov 7, 2025, 03:10 PM
HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $9
📈 PositiveBenzinga•Nov 7, 2025, 11:37 AM
Sana Biotechnology Q3 Adj. EPS $(0.15) Beats $(0.18) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 10:13 PM
Citizens Maintains Market Outperform on Sana Biotechnology, Raises Price Target to $8
📈 PositiveBenzinga•Oct 30, 2025, 12:55 PM
Sana Biotech surges as Eric Jackson calls it a 100-bagger
📈 PositiveSeeking Alpha•Oct 15, 2025, 02:37 PM
Wedbush Initiates Coverage On Sana Biotechnology with Outperform Rating, Announces Price Target of $5
📈 PositiveBenzinga•Sep 24, 2025, 01:28 PM
Sana Biotechnology drops 13% on $75M stock issuance, prices at $3.35
📉 NegativeSeeking Alpha•Aug 7, 2025, 04:52 AM
Frequently Asked Questions about SANA
What is SANA's current stock price?
Sana Biotechnology, Inc. (SANA) is currently trading at $4.36 per share. The stock has moved -3.11% today.
What is the analyst price target for SANA?
The average analyst price target for SANA is $8.00, based on 1 analyst.
What sector is Sana Biotechnology, Inc. in?
Sana Biotechnology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SANA's market cap?
Sana Biotechnology, Inc. has a market capitalization of $1.16 billion, making it a small-cap company.
Does SANA pay dividends?
No, Sana Biotechnology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to SANA for comparison